Video Experimental Relacionado
Updated: May 6, 2026
08:56
Transient Expression in Nicotiana Benthamiana Leaves for Triterpene Production at a Preparative Scale
Published on: August 16, 2018
18.3K
Alcanzar frutos colgantes en el descubrimiento de medicamentos en las interfaces proteína-proteína
James A Wells1, Christopher L McClendon
1Department of Pharmaceutical Chemistry, University of California at San Francisco, 1700 4th Street 503A, San Francisco, California 94156, USA. jim.wells@ucsf.edu
Nature
|December 14, 2007
Resumen
El descubrimiento de pequeñas moléculas para interrumpir las interacciones proteína-proteína es un desafío, pero alcanzable. Éxitos recientes muestran que estos fármacos pueden unirse eficazmente a las proteínas.
Área de la Ciencia:
- Descubrimiento y desarrollo de fármacos.
- Biología molecular La biología molecular.
- La bioquímica es la bioquímica.
Sus antecedentes:
- Las interacciones proteína-proteína (IPP) son cruciales en los procesos biológicos.
- La orientación de los IPP ofrece un potencial terapéutico significativo.
- El desarrollo de pequeñas moléculas para interrumpir los IBP presenta un gran desafío.
Objetivo del estudio:
- Explorar la viabilidad de apuntar a las interfaces proteína-proteína con pequeñas moléculas.
- Para resaltar los avances recientes en el descubrimiento de drogas que interrumpen el PPI.
- Para evaluar el potencial terapéutico de las pequeñas moléculas dirigidas a los IBP.
Principales métodos:
- Identificación de pequeñas moléculas que se unen a las interfaces de interacción proteína-proteína.
- Caracterización de la afinidad de unión y modo de interacción.
- Evaluación de las propiedades similares a las drogas y el potencial terapéutico.
Principales resultados:
- Estudios recientes han identificado pequeñas moléculas con potencia parecida a la de un fármaco contra los IBP.
- Estas pequeñas moléculas se unen a puntos críticos en las superficies de las proteínas.
- La eficiencia de unión y la profundidad de las pequeñas moléculas exceden a las de las proteínas naturales.
Conclusiones:
- Las interfaces proteína-proteína son más susceptibles a las drogas de lo que se suponía anteriormente.
- Las moléculas pequeñas que se dirigen a los puntos de acceso de PPI son prometedoras para la intervención terapéutica.
- Varios de estos fármacos candidatos están avanzando a través de ensayos clínicos.
Más Videos Relacionados
11:44Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
Published on: January 19, 2022
2.2K
09:36Author Spotlight: Discovering New Alkaloids in Plants with Advanced Mass Spectrometry Techniques
Published on: March 8, 2024
1.6K
Videos de Conceptos Relacionados
01:26Drug Discovery: Overview
10.4K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.4K
01:16Drug Biotransformation: Overview
3.7K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
3.7K
01:24Principles of Drug Action
9.4K
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
9.4K
01:26Targets for Drug Action: Overview
9.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.4K
01:29Pharmacogenomics: Identification of New Drug Targets
129
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129
01:30Production of Pharmaceuticals
100
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under...
100